Publication
Global rules on foreign direct investment (FDI)
Cross-border acquisitions and investments increasingly trigger foreign direct investment (FDI) screening requirements.
Author:
United States | Publication | April 15, 2021
On April 13, 2021, Acting Federal Trade Commission Chair Rebecca Kelly Slaughter announced that she had appointed Marta E. Wosińska to lead the FTC's Bureau of Economics. Dr. Wosińska is set to join the FTC later this month. With a background in the economics of healthcare and pharmaceuticals markets, Dr. Wosińska's appointment will likely strengthen the FTC's enforcement against mergers in the healthcare and pharmaceutical spaces.
Dr. Wosińska will be leading a Bureau with significant experience in analyzing healthcare and pharmaceutical mergers, which accounted for nearly half of all FTC enforcement actions in 2020. With the recent announcement that the FTC has joined a multilateral working group with the Department of Justice, state attorneys general, and various foreign antitrust enforcers to update the approach to analyzing the effects of pharmaceutical mergers, Dr. Wosińska may also have a significant impact on the future of pharmaceutical merger review.
Dr. Wosińska joins the FTC from the Duke-Margolis Center for Health Policy at Duke University. Her government experience includes previous roles as the Chief Healthcare Economist in the HHS Office of the Inspector General and the Director for Economics Staff at the FDA Center for Drug Evaluation and Research. Although the current Commissioners unanimously approved the appointment of Dr. Wosińska, permanent Commissioner appointments are still pending, which leaves room for additional staffing changes later on.
Norton Rose Fulbright has significant experience in healthcare and pharmaceutical antitrust matters. We would be pleased to assist healthcare and pharmaceutical companies in monitoring the FTC's evolving approach to investigating healthcare and pharmaceutical matters and developing ways to navigate the FTC review process.
Publication
Cross-border acquisitions and investments increasingly trigger foreign direct investment (FDI) screening requirements.
Publication
On February 2, 2024, the Belgian Presidency of the Council of the European Union confirmed that the Committee of Permanent Representatives had signed the Artificial Intelligence (AI) Regulation, referred to as the AI Act. Approval by the EU Parliament followed on 13 March 2024, and the AI Act is likely to appear in the EU’s Official Journal around May 2024. The AI Act aims to establish a stringent legal framework governing the development, marketing, and utilisation of artificial intelligence within the region, thereby marking a significant advancement in the regulation of this burgeoning domain.
Publication
The EU’s Artificial Intelligence Regulation, commonly referred to as the AI Act, is expected to come into force during the summer of 2024 (the AI Act). The AI Act will be the first comprehensive legal framework for the use and development of artificial intelligence (AI), and is intended to ensure that AI systems developed and used in the EU are safe, transparent, traceable, non-discriminatory and environmentally friendly.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023